Merck Splits Business to Separate Oncology from Non-Cancer Drugs

Merck is restructuring its business by separating its oncology division from non-cancer drug operations, a move reportedly in preparation for the 2028 patent expiry of its blockbuster cancer treatment, Keytruda.